Today's Information

Provided by: Qisda Corporation
SEQ_NO 1 Date of announcement 2022/05/20 Time of announcement 16:21:55
Subject
 The Company participates in TCI GENE INC.'s
private placement of common shares
Date of events 2022/05/20 To which item it meets paragraph 20
Statement
1.Name and nature of the underlying assets (if preferred shares, the terms
and conditions of issuance shall also be indicated, e.g., dividend yield,
etc.):
 TCI GENE INC.'s common shares in a private placement
2.Date of occurrence of the event:2022/05/20
3.Amount, unit price, and total monetary amount of the transaction:
Qisda Corporation
Number of Shares: 4,720,000 shares
Price per Share: NTD$ 115.5
Amount: NTD$ 545,160,000
4.Trading counterparty and its relationship with the Company (if the trading
counterparty is a natural person and furthermore is not a related party of
the Company, the name of the trading counterparty is not required to be
disclosed):
TCI GENE INC. is not the Company's related party.
5.Where the trading counterparty is a related party, announcement shall also
be made of the reason for choosing the related party as trading counterparty
and the identity of the previous owner, its relationship with the Company
and the trading counterparty, and the previous date and monetary amount of
transfer:
NA
6.Where an owner of the underlying assets within the past five years has
been a related party of the Company, the announcement shall also include the
date and price of acquisition and disposal by the related party, and its
relationship with the Company at the time of the transaction:
NA
7.Matters related to the current disposal of creditors' rights (including
types of collaterals of the disposed creditor's rights; if creditor's
rights over a related party, announcement shall be made of the name of the
related party and the book amount of the creditor's rights, currently being
disposed of, over such related party):
NA
8.Profit or loss from the disposal (not applicable in cases of acquisition
of securities) (those with deferral should provide a table explaining
recognition):
NA
9.Terms of delivery or payment (including payment period and monetary
amount), restrictive covenants in the contract, and other important terms
and conditions:
Payment by wired
10.The manner of deciding on this transaction (such as invitation to tender,
price comparison, or price negotiation), the reference basis for the
decision on price, and the decision-making unit:
decision-making department: Board Resolution
Reference Price Basis: According to the price of
TCI GENE INC.'s private placement of common shares and
the reasonableness opinion issued by the CPA.
The decision-making department: The Company's board of directors meeting.
11.Net worth per share of the Company's underlying securities acquired or
disposed of:17.72
12.Cumulative no.of shares held (including the current transaction), their
monetary amount, shareholding percentage, and status of any restriction of
rights (e.g., pledges), as of the present moment:
Qisda Corporation
Number of Shares: 4,720,000 shares
Amount: NTD$ 545,160,000
Percentage of Shareholding: around 17.84%
Restriction on rights: Transferring shares has to follow relevant provisions
regarding private placement in Securities and Exchange Act
13.Current ratio of securities investment (including the current trade, as
listed in article 3 of Regulations Governing the Acquisition and Disposal of
Assets by Public Companies) to the total assets and equity attributable to
owners of the parent as shown in the most recent financial statement and
working capital as shown in the most recent financial statement as of the
present:
Current ratio of long or short term securities investment (including the
current trade approved by board of directors) to the total assets: 52.52%
Current ratio of long or short term securities investment (including the
current trade approved by board of directors) to the shareholder's equity:
141.67%
Operating Capital: NTD$  -6,919,740 thousand.
Source of funds:Self-owned capital
purpose of the acquisition:
In order to strengthen the company's biotechnology industry, it has
stepped into the field of precision medicine. Through this investment,
we will complement each other's resources, expand the biotechnology
and medical care business, and provide customers with a wider
range of products and services.
14.Broker and broker's fee:No
15.Concrete purpose or use of the acquisition or disposal:
In order to strengthen the company's biotechnology industry, it has
stepped into the field of precision medicine. Through this investment,
we will complement each other's resources, expand the biotechnology
and medical care business, and provide customers with a wider
range of products and services.
16.Any dissenting opinions of directors to the present transaction:No
17.Whether the counterparty of the current transaction is
a related party:No
18.Date of the board of directors resolution:NA
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an unreasonable opinion regarding the current
transaction:No
21.Name of the CPA firm:WeTec International CPAs
22.Name of the CPA:Lai Ming-Yang
23.Practice certificate number of the CPA:
Taipei City CPA Certificate No. 2123
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:No
26.Details on transactions with the counterparty for the past year and the
expected coming year:No
27.Source of funds:Self-owned capital
28.Any other matters that need to be specified:
No

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Qisda Corporation published this content on 20 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 May 2022 08:24:09 UTC.